Arthritis, Rheumatoid
Conditions
Brief summary
A prospective, open-label, single center, study to evaluate pharmacokinetics and dosimetry of intravenously injected Tc 99m tilmanocept at three mass doses (50 µg, 200 µg, and 400 µg) radiolabeled with 10 millicuries (mCi) Tc 99m.
Interventions
DRUGTilmanocept
Intravenously administered Technetium Tc 99m tilmanocept
Sponsors
Navidea Biopharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures. 2. The subject is 30 - 65 years of age at the time of consent. 3. Has a negative urine drug screening for illicit or unprescribed drugs suggestive of drug abuse. 4. Subjects will have a BMI of 18 to 34 kg/m2, inclusive, at Screening 5. The subject has active RA as determined by the Clinical Disease Activity Index score of ≥ 10 and have ≥ 2 swollen joints. 6. If the subject is receiving methotrexate, they have been at a stable dose for \> 4 weeks prior to the Day 1 visit. 7. If the subject is receiving biologic therapy or other DMARDs, they have been at a stable dose \> 8 weeks prior to the Day 1 visit. 8. If the subject is receiving NSAIDS or oral corticosteroids, the dose has been at a stable dose for \> 4 weeks prior to the Day 1 visit. The corticosteroid dose should be ≤ 10mg/day of prednisone or an equivalent steroid dose. 9. Aside from being diagnosed with rheumatoid arthritis, subjects must be in good health, as determined by medical history, physical examination, vital sign assessment, 12 lead electrocardiogram (ECG) and clinical laboratory evaluations.
Exclusion criteria
1. The subject is pregnant or lactating. 2. The subject has a significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator) 3. The subject has a history of significant hypersensitivity, intolerance, or allergy to dextran or modified forms of dextran; unless approved by the Investigator 4. The subject has a history or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant 5. The subject has participated in a radiolabeled investigational study drug trial within 3 months prior to Day 1 6. The subject has exceeded yearly radioactive dose of 30 millisieverts (mSv) 7. The subject has a history of drug abuse or alcohol within 2 years before dose administration, or positive drug or alcohol test at screening. 8. The subject has used tobacco- or nicotine-containing products (including but not limited to cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to Day 1, or positive cotinine screen 9. The subjects uses any prescription medications within 14 days prior to Day 1, except as allowed by the inclusion criteria or as deemed acceptable by the Investigator; 10. The subject uses any over-the-counter, non-prescription preparations (including vitamins, minerals, and phytotherapeutic/ herbal/plant-derived preparations) within 7 days prior to Day 1, unless deemed acceptable by the Investigator; 11. The subject has poor peripheral venous access; 12. The subject has donated blood within 30 days prior to Day 1, or plasma within 2 weeks prior to Day 1 13. The subject has received blood products within 2 months prior to Day 1; 14. The subject has any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study. 15. The subject has received any radiopharmaceutical within 7 days prior to the administration of Tc 99m tilmanocept.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Systemic Clearance (CLs) of Technetium Tc 99m Tilmanocept | 3 Days | Systemic Clearance (CLs) of Technetium Tc 99m Tilmanocept |
| Maximum Plasma concentration (Cmax) of Technetium Tc 99m Tilmanocept | 1 Days | Maximum Plasma concentration (Cmax) of Technetium Tc 99m Tilmanocept |
| Plasma Area Under the Curve (AUC) of Technetium Tc 99m Tilmanocept | 2 Days | Plasma Area Under the Curve (AUC) of Technetium Tc 99m Tilmanocept |
| Clinical Dosimetry of Technetium Tc 99m Tilmanocept | 3 days | Clinical Dosimetry of Technetium Tc 99m Tilmanocept |
| Renal Clearance (CLr) of Technetium Tc 99m Tilmanocept | 2 days | Renal Clearance (CLr) of Technetium Tc 99m Tilmanocept |
| Terminal Elimination Half-Life (T1/2) of Technetium Tc 99m Tilmanocept | 3 days | Terminal Elimination Half-Life (T1/2) of Technetium Tc 99m Tilmanocept |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events | 7 Days | Incidence of Adverse Events |
Outcome results
None listed